Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Historically, there have been few therapies developed for the treatment of chronic obstructive pulmonary disease (COPD), a life threatening, progressive obstructive respiratory disease that interferes with normal breathing and has detrimental effects on quality of life.
In the 25 years between 1982 and 2008 only a handful of drugs were approved for COPD2 . Those drugs included Boehringer Ingelheim’s Spiriva (tiotropium), a long-acting muscarinic antagonist (LAMA), and twice-daily inhaled fixed dose combinations (FDCs) of long acting beta 2 adrenoceptor agonist (LABA) plus inhaled corticosteroid (ICS). GlaxoSmithKline’s (GSK) Advair (fluticasone propionate + salmeterol) and AstraZeneca (AZ) Symbicort, (budesonide + formoterol) were initially approved for asthma and their label expansions for COPD in 2008 ushered in the use of FDC therapies for symptom relief and maintenance therapy in that indication. In the past decade, as COPD clinical development intensified, the focus shifted towards developing FDCs of two novel bronchodilators. Four recently approved FDCs were developed, as dry powder formulations, specifically for moderate to severe COPD patients, and aimed to deliver once-daily symptom relief and maintenance treatment.
In this report we provide insights from Citeline’s Pharmaprojects and Trialtrove data into how these FDCs are carving out distinctive niches and what pipeline status FDCs are poised to enter this now competitive market in the near future.
In this report, we provide insights from Citeline’s Pharmaprojects and Trialtrove data into how fixed-dose combinations (FDCs) of two novel bronchodilators are carving out distinctive niches and the probable pipeline status we will see as FDCs enter the now competitive market for chronic obstructive pulmonary disease (COPD).
Request a Demo
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
How can we help you?
Our team is always happy to hear from you. Please call us at:
Pharma Report Store
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now:
Citeline is the industry’s most comprehensive, reliable and current global R&D intelligence suite of solutions that can help you gain critical insights into the global clinical trial landscape and realize greater cost-savings as you develop on your clinical trial programs.
Built by experts. Made for experts.
Trialtrove is the go-to resource for clinical trial research. Easily track your competitors' clinical R&D activity with expert insights and continually monitored trials.
Over 450,000 investigators from 170,000+ sites in 180+ countries, all with clinical trial experience, at your fingertips. Support your trial success and inform your principal investigator (PI) and site selection activities with Sitetrove.
Looking for more products Product Finder
